We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

By LabMedica International staff writers
Posted on 18 Jul 2024
Print article
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide. Many adults avoid routine blood tests due to their complexity and the long wait times for results, which can lead to delayed interventions or missed diagnoses, resulting in substantial avoidable costs. Now, a groundbreaking diagnostic platform is set to transform the existing global infrastructure by providing lab-accurate, actionable test results that aid in the early detection and prevention of chronic conditions.

Truvian Health (San Diego, CA, USA) has developed an automated benchtop system that allows simple, accurate, and comprehensive routine blood tests to be conducted directly in clinics, doctor’s offices, and pharmacies. Utilizing patented technologies and intelligent integration, Truvian’s compact device offers a convenient and economical alternative to traditional off-site labs, delivering quick, lab-accurate results from just a small blood sample, and enhancing healthcare decision-making. The Truvian system combines clinical chemistry, immunoassay, and hematology tests in one operation and can simultaneously handle multiple types of assays. Its initial offering, a comprehensive wellness panel, covers over 90% of the most commonly requested routine blood tests, requiring only one tube and 8 drops of blood.

Truvian has shared data from various independent clinical studies showing that its system's results match those from central laboratories across an extensive range of tests. The platform has been tested with over 50,000 samples from approximately 5,000 donors to date, achieving a reliability rate of over 98%. This system’s capability to provide central lab-quality results in any setting could fundamentally change the way chronic diseases are detected and managed. Immediate access to results enables healthcare providers to diagnose and treat patients without delay, enhancing patient involvement in their health decisions and improving outcomes. By consolidating blood diagnostics into a single visit, the platform reduces healthcare costs for both patients and systems, simplifies the monitoring and management of chronic conditions, and promotes healthier, longer lives. Truvian is now working towards securing US Food and Drug Administration (FDA) clearance for its blood testing platform.

“We are on the cusp of delivering what the world needs to counter today’s non-communicable disease burden and unsustainable healthcare costs,” said Jay Srinivasan, chief executive officer of Truvian.

Related Links:
Truvian Health

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Echinococcus Granulosus Assay
Echinococcus Granulosus IgG ELISA
New
Myocardial Infarction Test
Savvycheck SensA Heart

Print article

Channels

Molecular Diagnostics

view channel
Image: The lateral flow test could detect prostate cancer more quickly and with greater accuracy (Photo courtesy of Valley Diagnostics)

Groundbreaking Test Could Detect Prostate Cancer Within Minutes Via Urine Sample

In the UK, over 52,000 men are diagnosed with prostate cancer annually, with up to one-quarter of these cases identified at a later stage, requiring more intensive treatments. The cost to the NHS for these... Read more

Immunology

view channel
Image: Concept for the device. Memory B cells able to bind influenza virus remain stuck to channels despite shear forces (Photo courtesy of Steven George/UC Davis)

Microfluidic Chip-Based Device to Measure Viral Immunity

Each winter, a new variant of influenza emerges, posing a challenge for immunity. People who have previously been infected or vaccinated against the flu may have some level of protection, but how well... Read more

Microbiology

view channel
Image: The iFAST reader scans 5000 individual bacteria with each sample analyzed in less than a minute (Photo courtesy of iFAST)

High-Throughput AST System Uses Microchip Technology to Rapidly Analyze Bacterial Samples

Bacteria are becoming increasingly resistant to antibiotics, with resistance levels ranging from 20% to 98%, and these levels are unpredictable. Currently, antimicrobial susceptibility testing (AST) takes... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.